Research presented at the 2026 Alzheimer's Association International Conference (AAIC) linked higher blood p-tau217—a form of phosphorylated tau protein—to later cognitive impairment. For family caregivers, the study offers evidence about risk in cognitively healthy older adults, rather than proof that screening improves outcomes. The Alzheimer's Association reported the findings at AAIC 2026 in London, alongside an original study published in JAMA. The key distinction for families is between estimating a group's risk and predicting what will happen to one person.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who did the study follow?
- What did the risk estimates measure?
- How far can families take the prediction?
- Should a symptom-free relative seek testing?
Who did the study follow?
According to the JAMA study, researchers pooled 2,684 cognitively unimpaired adults from six observational and clinical-trial cohorts. These groups came from North America, Japan and Australia. Participants had a median age of 69.6 years, and 63% were female.
During a median 5.4 years of follow-up, 478 developed cognitive impairment; the longest follow-up reached 13.5 years. Researchers examined whether baseline plasma p-tau217 levels predicted subsequent impairment. This design measures a predictive relationship. It does not test whether offering blood screening leads to better health, daily functioning or care.
What did the risk estimates measure?
JAMA reported an estimated 38% five-year risk of cognitive impairment in the very-high-p-tau217 group, compared with 24% in the high group. The very-high category meant levels above 2.5 standard deviations, a statistical measure of distance from a reference average. The 38% estimate had a 95% confidence interval of 33%–43%, expressing uncertainty around the group estimate.
As an illustration, 38% means about 38 of 100 comparable participants would be expected to reach the study's impairment endpoint within five years. That endpoint included mild cognitive impairment, dementia or two consecutive global Clinical Dementia Rating scores of at least 0.5. The rating was another way the study identified impairment. These percentages therefore describe a broader outcome than Alzheimer's dementia alone.
How far can families take the prediction?
JAMA reported that higher p-tau217 remained associated with progression after researchers accounted for factors including amyloid PET measurements. That supports its predictive value beyond those measurements, while still leaving the results as estimates of risk. Mass General Brigham's report on the findings described an estimated 78% ten-year risk in the very-high group. Researchers cautioned that ten-year and later estimates relied on much sparser data.
The longest follow-up should not be mistaken for the follow-up available for most participants. The investigators also identified selection bias and limited population representativeness. People enrolled in these cohorts may differ from those seen in everyday care. Broader validation is needed before families use these percentages as reliable individual or lifetime forecasts.
Should a symptom-free relative seek testing?
Senior author Reisa Sperling advised against currently available blood testing for asymptomatic people, according to Mass General Brigham's account of her guidance. She cited the absence of preventive disease-modifying treatments for that group and identified prevention-trial recruitment as a present use. Sperling also said that advice about exercise, diet and sleep would remain unchanged by testing.
For a family considering a test, the practical question is what a result would change in the person's care. Before pursuing testing, ask the clinician to explain its purpose, how the result would be interpreted and what action would follow. If the purpose is prevention research, ask whether the test is part of a trial's recruitment process.
You Might Also Like
- The NIA 2026 Dementia Care and Caregiving Summit Report: Questions Family Caregivers Can Ask Local Care Programs
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: Questions Family Caregivers Can Ask Local Care Programs
- Strengths-Based Dementia Care in the 2026 NIA Report: What the Report Means for Family Caregivers
